Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.
about
Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alphaHistone deacetylases as targets for treatment of multiple diseasesHDAC inhibition decreases the expression of EGFR in colorectal cancer cells.Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agentsHistone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.Epigenetic changes in prostate cancer: implication for diagnosis and treatment.Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.Attenuation of choroidal neovascularization by histone deacetylase inhibitor.Histone deacetylase inhibitors in clinical development.Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance?Enhancing the anti-angiogenic action of histone deacetylase inhibitors.Development of novel therapeutic strategies that target HIF-1.Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?The role of histone deacetylases in prostate cancer.Targeting tumor angiogenesis with histone deacetylase inhibitors.Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer.The role of histone deacetylases (HDACs) in human cancer.Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi‑1 leukemia cells.Targeting the hypoxia-inducible factor (HIF) pathway in cancer.Finding the place of histone deacetylase inhibitors in prostate cancer therapy.Epigenetic regulation of hypoxia inducible factor in diseases and therapeutics.Romidepsin for the treatment of non-Hodgkin's lymphoma.The discovery and development of romidepsin for the treatment of T-cell lymphoma.A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).HDAC inhibition upregulates the expression of angiostatic ADAMTS1.Systemic co-administration of depsipeptide selectively targets transfection enhancement to specific tissues and cell types.
P2860
Q24308024-58C10E32-8B4A-4604-B66F-85AADB9EBE60Q27000389-00D55AED-3D81-4B7B-AA6E-98A86AD84FB2Q33862612-25F935BD-0DDC-4685-AF1C-CCEAC5ADF0F7Q34055631-49E57D58-7222-4CB4-B064-9676FC8CAB85Q34382527-96161477-B3D2-445E-BA41-DC31C28F8319Q34385658-B8414F42-D695-4002-9745-DA3B44E73C2FQ34399444-CB1E6479-0397-4031-93DB-5046F4604029Q35217263-5B2D1D29-A70A-4F85-A806-D93851934A1FQ35609717-47492FA3-81C5-48C1-8B87-BB2189BD15CFQ35911749-4EC49034-86D0-4C85-9C82-B45058D39236Q36179533-5F44D0BA-689A-4D59-9302-5F228870C64AQ36325361-98C6F23E-A5CC-4648-8C2D-E1239AAB1BD5Q36425968-DE764378-FFBC-4351-9A56-923F87440060Q37317209-C81D89AB-B4FF-4045-85D3-F0D645405AB6Q37333510-0FA7B980-4A0A-42B8-B308-7D719694850DQ37359115-733FCEBC-E9E4-4689-8170-36B53CCE9A3BQ37416288-0B6C69CA-DE9C-4834-BD6D-E158B28BDC0BQ37453782-323ACE90-7F54-4820-8940-B5FFE89747F0Q37496300-F1903D2B-757B-4108-9B21-FEE78D929BABQ37587446-F3F1F8FA-01DC-4188-81D8-8A446ABD556EQ37960198-EEA4F447-5280-4B4A-903E-29CC35A584F6Q38084610-2503A637-83DB-4EF7-A601-56FC3FEFA317Q38455740-7CADD1C7-8A20-44F7-9501-6980FF4E3D69Q38713744-168B3CAA-A792-45C9-8E73-AD1E6CB1BA61Q39248784-449E7485-553D-4299-A8E6-6BDDD190ECEEQ39917342-D50F77E9-0EB3-4204-B570-817256C1519AQ40248360-B7837F9E-2717-483F-88F7-D5F22521EE95
P2860
Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Antitumor efficacy of FK228, a ...... ssion of angiogenesis factors.
@en
Antitumor efficacy of FK228, a ...... ssion of angiogenesis factors.
@nl
type
label
Antitumor efficacy of FK228, a ...... ssion of angiogenesis factors.
@en
Antitumor efficacy of FK228, a ...... ssion of angiogenesis factors.
@nl
prefLabel
Antitumor efficacy of FK228, a ...... ssion of angiogenesis factors.
@en
Antitumor efficacy of FK228, a ...... ssion of angiogenesis factors.
@nl
P2093
P1476
Antitumor efficacy of FK228, a ...... ssion of angiogenesis factors.
@en
P2093
Masahiko Matsuo
Seitaro Mutoh
Takahisa Noto
Takeshi Inoue
Tatsuya Sasakawa
Toshitaka Manda
Yoshinori Naoe
Yuka Sasakawa
P304
P356
10.1016/S0006-2952(03)00411-8
P407
P577
2003-09-01T00:00:00Z